HeXun Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	147.22	33.49	-5.19	-42.99
Depreciation & Amortization	23.52	19.1	14.19	11.43
Other Amortization	1.2	1.2	0.53	0.48
Loss (Gain) From Sale of Assets	0.01	0.05	-0.02	-0.2
Stock-Based Compensation	-	-	0.3	-
Other Operating Activities	13.97	-0.07	-0.05	0.47
Change in Accounts Receivable	-62.39	-17.3	-4.98	-
Change in Inventory	-10.98	-4.6	-	-
Change in Accounts Payable	1.81	-0.8	0.42	-4.3
Change in Unearned Revenue	6.97	-3.37	5.1	-
Change in Other Net Operating Assets	-0.4	15.39	0.93	-0.39
Operating Cash Flow	120.92	43.09	11.23	-35.5
Operating Cash Flow Growth	180.62%	283.77%	-	-
Capital Expenditures	-37.29	-20.67	-1.23	-
Sale of Property, Plant & Equipment	-	-	0.13	8.84
Sale (Purchase) of Intangibles	-	-0.64	-5.96	-
Investment in Securities	-100	-	-72	-
Other Investing Activities	-	-3.97	-	-35.78
Investing Cash Flow	-137.29	-25.28	-79.05	-26.95
Long-Term Debt Repaid	-40.31	-4.88	-2.46	-2.01
Net Debt Issued (Repaid)	-40.31	-4.88	-2.46	-2.01
Issuance of Common Stock	-	125	105	78
Other Financing Activities	-	-	-	-0.2
Financing Cash Flow	-40.31	120.12	102.54	75.79
Net Cash Flow	-56.68	137.93	34.72	13.34
Free Cash Flow	83.63	22.42	10	-35.5
Free Cash Flow Growth	272.98%	124.19%	-	-
Free Cash Flow Margin	29.20%	17.17%	20.22%	-
Free Cash Flow Per Share	1.82	0.49	0.27	-1.16
Cash Interest Paid	1.24	1.79	1.64	1.57
Levered Free Cash Flow	33.7	9.68	0.46	-
Unlevered Free Cash Flow	34.43	10.84	1.48	-
Change in Net Working Capital	50.32	5.26	0.75	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.